Lipoprotein(a) in the Evaluation of Cardiovascular Risk in the Portuguese Population

Authors

  • Joaquim A. Meireles-Brandão Faculty of Medicine. University of Porto. Porto. Starmedica Clinica. Paredes.
  • Lúcia R. Meireles-Brandão Starmedica Clinica. Paredes.
  • Rui Coelho Faculty of Medicine. University of Porto. Porto.
  • Francisco R. Rocha-Gonçalves Faculty of Medicine. University of Porto. Porto.

DOI:

https://doi.org/10.20344/amp.10251

Keywords:

Atherosclerosis, Cardiovascular Diseases, Lipoprotein(a), Portugal, Primary Prevention

Abstract

Introduction: High values of lipoprotein(a), related to atherosclerosis progression, are often considered a marker of thrombosis. We assessed the lipoprotein(a) profile in a group of patients with high vascular risk and no cardiovascular events, established its correlation with other cardiovascular risk factors and inferred the results for patients with metabolic disorders and, at least, two risk factors.
Material and Methods: This longitudinal observational study included 516 patients, who had at least two cardiovascular risk factors and regularly attended, for at least two years, the outpatient consultations at a clinic of metabolism and vascular risk for primary prevention. Sociodemographic, clinical and anthropometric parameters were obtained at the baseline visit. Hepatic morphology was assessed in 509 patients (98.6%) by ultrasonography. The 10-year vascular risk was estimated using Framingham risk score, atherosclerotic cardiovascular disease and systematic coronary risk evaluation tables.
Results: Significant correlations were found between lipoprotein(a) levels and the addressed vascular risk factors, as well as between lipoprotein(a), and Framingham risk score, atherosclerotic cardiovascular disease and systematic coronary risk evaluation charts. Lipoprotein(a) values were also considerably higher in patients with steatosis.
Discussion: Increased lipoprotein(a) values were directly associated with all markers of cardiovascular risk and with non-alcoholic hepatic steatosis.
Conclusion: Due to its high availability and low cost, lipoprotein(a) should become part of the routine evaluation of patients at vascular risk.

Downloads

Download data is not yet available.

Downloads

Published

2019-03-29

How to Cite

1.
Meireles-Brandão JA, Meireles-Brandão LR, Coelho R, Rocha-Gonçalves FR. Lipoprotein(a) in the Evaluation of Cardiovascular Risk in the Portuguese Population. Acta Med Port [Internet]. 2019 Mar. 29 [cited 2024 May 25];32(3):202-7. Available from: https://actamedicaportuguesa.com/revista/index.php/amp/article/view/10251

Issue

Section

Original